Prostate-Specific Antigen Levels of Prostate Cancer Patients Three Months Following LHRH Agonist Therapy

Prostate-Specific Antigen Levels of Prostate Cancer Patients Three Months Following LHRH Agonist Therapy

Andy Andy

Contact

Robertus Bebet Prasetyo

Contact

University of Indonesia

Prostate-Specific Antigen Levels of Prostate Cancer Patients Three Months Following LHRH Agonist Therapy

Article Fingerprint

ReserarchID

47EO1

Prostate-Specific Antigen Levels of Prostate Cancer Patients Three Months Following LHRH Agonist Therapy Banner

AI TAKEAWAY

Connecting with the Eternal Ground

References

16 Cites in Article

Reference Format

Otis Brawley (2012). Prostate cancer epidemiology in the United States.
M Parkin,S Whelan,J Ferlay,L Rteppo,D Thomas (2002). Cancer incidence in five continents(Volume VIII).
R Siegel,E Ward,O Brawley,A Jemal (2011). Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.
Charles Huggins,Clarence Hodges (1941). Studies on Prostatic Cancer.
Osamu Ishizuka,Osamu Nishizawa,Shuji Nishizawa,Tomoya Satoh,Masahisa Wajiki,Hideo Kiyokawa,Yoshihiro Inoue,Shinya Kobayashi,Hiroya Mizusawa,Tatsuo Nakagawa (2013). Comparison of efficacy and safety of 1- and 3-month luteinizing hormone-releasing hormone agonist depots as initial therapies for prostate cancer.
Valdo Solang,Alwin Monoarfa,Ferdinand Tjandra (2013). Profil penderita kanker prostat di RSUP Prof. Dr. R. D. Kandou Manado periode tahun 2013–2015.
N Clarke,M De Santis,A Costello,Y-H Chang,T Pickles,A Pompeo,S Bazarbashi,G Haas,M Cooperberg (2016). Global treatment patterns for late-stage prostate cancer: Updated results from ASPIRE-PCa.
B Hellerstedt,K Pienta (2009). The Current State of Hormonal Therapy for Prostate Cancer.
Patrizia Limonta,Marina Marelli,Roberta Moretti (2001). LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action.
Hein Van Poppel,Laurence Klotz (2012). Gonadotropin‐releasing hormone: An update review of the antagonists versus agonists.
P O'brien M F, Cronin A M, Fearn,B Smith,J Stasi,B Guillonneau (2009). Pretreatment prostatespecific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
D Palma,S Tyldesley,P Blood,M Liu,J Morris,T Pickles (2007). Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy.
T Choueiri,W Xie,D' Amico,R Ross,J C Hu,M Pomerantz (2009). Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.
Fabio Cury,Daniel Hunt,Mack Roach,William Shipley,Elizabeth Gore,I‐chow Hsu,Robert Krisch,Michael Seider,Howard Sandler,Colleen Lawton (2013). Prostate‐specific antigen response after short‐term hormone therapy plus external‐beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413.
Élcio Silva,Ubirajara Ferreira,Wagner Matheus,Eliney Faria,Gustavo Silva,Minori Saito,Auro De Souza,Azuil Laranjo,Otavio Clark,Luis Magna,Lísias Castilho,Leonardo Reis (2012). Goserelin versus leuprolide in the chemical castration of patients with prostate cancer.
Yasuhisa Fujii,Junji Yonese,Satoru Kawakami,Shinya Yamamoto,Yuhei Okubo,Iwao Fukui (2008). Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.

Download References

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

How to Cite This Article

Andy Andy. 2019. \u201cProstate-Specific Antigen Levels of Prostate Cancer Patients Three Months Following LHRH Agonist Therapy\u201d. Global Journal of Medical Research - F: Diseases GJMR-F Volume 19 (GJMR Volume 19 Issue F6).

More Citation Formats

Select Citation Style:

Download Citation

GJMR Volume 19 Issue F6

Explore Journals Explore Volume Read This Issue

Journal Specifications

Crossref Journal DOI 10.17406/gjmra

Print ISSN 0975-5888

e-ISSN 2249-4618

Keywords

Not Found

Classification

GJMR-F Classification NLMC Code: WJ 752

QZ 20.5

Submission ReceivedDecember 16, 2018
Peer Review Double Blind
Handling Editor
Accepted January 1, 2019
Published January 15, 2019

Version of record

v1.2

Issue date

November 8, 2019

Language

Experiance in AR

Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.

View in VR

Read in 3D

Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.

View in 3D

Article Matrices

Total Views: 2664

Total Downloads: 1279

2026 Trends

Our website is actively being updated, and changes may occur frequently. Please clear your browser cache if needed. For feedback or error reporting, please email [email protected]